BeyondSpring Inc (BYSI) Price to Earnings Ratio

BeyondSpring, Inc. - graphic logo of issuer BYSI

The oncology sector is characterized by fierce competition with industry behemoths utilizing patent wars. BeyondSpring Inc. (BYSI) is currently seeing its share price squeezed by R&D costs and weak demand in China, with the indicator standing at -3.90. This price action for the securities on the GURU.Markets platform confirms the priced-in risks; however, BeyondSpring Inc. (BYSI) relies on its authority in developing immune support agents for chemotherapy.

BeyondSpring Pharma (BYSI) - Price to Earnings Ratio from 07/04/2022 to 11/09/2026

Comprehensive metric breakdowns and analytics for BeyondSpring Pharma (BYSI)

- price and consensus price forecast:
Stock Price beyondspringpharma.com|BYSI - Price Target Chart
- market capitalization details:
Market Value BeyondSpring Inc.|BYSI - Real Price to Acquire Entire Company
- book capitalization information:
Accounting Value of a Share BeyondSpring|BYSI - Company Book Value|Market-to-Book Ratio beyondspringpharma.com|BYSI - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio BeyondSpring Inc.|BYSI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio BeyondSpring Inc|BYSI - Company Debts|Debts to Book Value BeyondSpring Inc.|BYSI - Company Long-Term Debt|Company Short-Term Debt BeyondSpring|Immediate Liquidity beyondspringpharma.com
- earnings and valuation multiples indicators:
BYSI - Net Profit|Projected Net Profit BeyondSpring Inc.|BYSI - Price to Earnings Ratio|Projected Price to Earnings Ratio BeyondSpring, Inc.|BYSI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation BeyondSpring Inc.|BYSI - Operating profit before deduction of amortization|Earnings per share for the last four quarters BeyondSpring|BYSI - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months beyondspringpharma.com|BYSI - Earnings growth in current year|Expected net earnings per share growth next year BeyondSpring Inc.
Comprehensive company analysis:BYSI (beyondspringpharma.com)
Product sample of BeyondSpring Inc.

Investors utilize multiples to distinguish speculative movements from an asset's actual market value, verifying the issuer's long-term sustainability. The ratio of current market capitalization to annual net income, reflected through the forward P/E of BeyondSpring Inc. (BYSI), allows for an assessment of whether BeyondSpring Inc. (BYSI) is overbought given its Plinabulin patent protection and R&D partnerships, where inflated indicator values signal an increased risk of a price correction.

Analysis of competing companies

P/E Multiple incyte.com|Price to Earnings Ratio HUTCHMED (HCM)|Price to Earnings Ratio NUVB (Nuvation Bio Inc)|Day One Bio - Price to Earnings Ratio|Company Value to Net Income MNPR|INBX - Price to Earnings Ratio|Market Cap to Earnings I-Mab|Fennec Pharmaceuticals Inc. (FENC) - Price to Earnings Ratio|Price to Earnings Multiple HRTX|NVCT (Nuvectis) - P/E Multiple|Price to Earnings Ratio coherus.com (CHRS)|Price to Earnings Ratio Corbus Pharmaceuticals (CRBP)|CRDF - Market Cap to Earnings|Price to Earnings Ratio BioAtla BCAB|Lixte Biotechnology Holdings Inc. - Price to Earnings Ratio|CTXR - Price to Earnings Ratio|Market Cap to Earnings Cellectar Corp|BLRX: P/E Multiple|Market Cap to Net Income Ratio canfite.com CANF|Price to Earnings Ratio APRE|Market Cap to Earnings Kazia KZIA|Price to Earnings Ratio SLXN (Silexion Therapeutics Corp)|NCNA (nucana.com) - Company Value to Net Income|Chimerix, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio CYCC (cyclacel.com)|G1 Pharma - P/E Multiple|Company Value to Net Income KRON (Kronos Bio Inc)|KTRA: P/E Multiple|Market Cap to Earnings Oncternal Corp (ONCT)|Price to Earnings Ratio Portage Biotech Inc.